126 related articles for article (PubMed ID: 35636055)
21. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
22. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity.
Reinig EF; Greipp PT; Chiu A; Howard MT; Reichard KK
Mod Pathol; 2018 May; 31(5):705-717. PubMed ID: 29327715
[TBL] [Abstract][Full Text] [Related]
23. P53 gene mutations in acute myeloid leukemia with 17p monosomy.
Fenaux P; Jonveaux P; Quiquandon I; Laï JL; Pignon JM; Loucheux-Lefebvre MH; Bauters F; Berger R; Kerckaert JP
Blood; 1991 Oct; 78(7):1652-7. PubMed ID: 1912553
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes and characteristics of patients with
Bewersdorf JP; Shallis RM; Gowda L; Wei W; Hager K; Isufi I; Kim TK; Pillai MM; Seropian S; Podoltsev NA; Gore SD; Siddon AJ; Zeidan AM
Leuk Lymphoma; 2020 Sep; 61(9):2180-2190. PubMed ID: 32362171
[TBL] [Abstract][Full Text] [Related]
25. The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.
Piqué-Borràs MR; Jevtic Z; Bagger FO; Seguin J; Sivalingam R; Bezerra MF; Louwagie A; Juge S; Nellas I; Ivanek R; Tzankov A; Moll UM; Cantillo O; Schulz-Heddergott R; Fagnan A; Mercher T; Schwaller J
Blood; 2023 May; 141(18):2245-2260. PubMed ID: 36735909
[TBL] [Abstract][Full Text] [Related]
26. Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.
Chisholm KM; Heerema-McKenney AE; Choi JK; Smith J; Ries RE; Hirsch BA; Raimondi SC; Alonzo TA; Wang YC; Aplenc R; Sung L; Gamis AS; Meshinchi S; Kahwash SB
Blood Adv; 2020 Dec; 4(23):6000-6008. PubMed ID: 33284945
[TBL] [Abstract][Full Text] [Related]
27. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
29. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
30. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
31. De Novo Pure Erythroid Leukemia With Rapid Progression and Multiple Lytic Bone Lesions: A Case Report.
Okazaki S
Cureus; 2023 Jul; 15(7):e41581. PubMed ID: 37559863
[TBL] [Abstract][Full Text] [Related]
32. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
33.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.
Tavor S; Rothman R; Golan T; Voskoboinik N; Katz BZ; Sarid N; Shomrat R; Orr-Urtreger A; Naparstek E
Leuk Lymphoma; 2011 Apr; 52(4):642-7. PubMed ID: 21323513
[TBL] [Abstract][Full Text] [Related]
35. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
[TBL] [Abstract][Full Text] [Related]
36. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
37. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.
Li B; An W; Wang H; Baslan T; Mowla S; Krishnan A; Xiao W; Koche RP; Liu Y; Cai SF; Xiao Z; Derkach A; Iacobucci I; Mullighan CG; Helin K; Lowe SW; Levine RL; Rampal RK
Blood; 2022 Jun; 139(25):3630-3646. PubMed ID: 35421216
[TBL] [Abstract][Full Text] [Related]
38. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
40. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Malcikova J; Stano-Kozubik K; Tichy B; Kantorova B; Pavlova S; Tom N; Radova L; Smardova J; Pardy F; Doubek M; Brychtova Y; Mraz M; Plevova K; Diviskova E; Oltova A; Mayer J; Pospisilova S; Trbusek M
Leukemia; 2015 Apr; 29(4):877-85. PubMed ID: 25287991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]